HB1525 prevents the Secretary of Health and Human Services from using or declaring a public health emergency under sections 319 or 319F–3 of the Public Health Service Act with respect to abortion and immediately terminates any such declaration in effect at enactment. The bill also directs HHS and FDA officials to reinstate and enforce a Risk Evaluation and Mitigation Strategy (REMS) requirement that abortion drugs be dispensed only in clinics, medical offices, or hospitals under a certified health care provider’s supervision, and it forbids exercising enforcement discretion to relax those REMS requirements.
Beyond reinstating an in-person dispensing rule, the bill ties any future reduction of REMS protections to a precondition: every State must submit standardized, aggregate abortion data to the CDC’s abortion surveillance system that includes a long list of mandatory variables. The measure therefore combines a procedural bar on federal emergency action with concrete, immediate limits on how abortion drugs may be distributed and a high statutory hurdle for changing those distribution rules.
At a Glance
What It Does
The bill forbids HHS from declaring a public health emergency concerning abortion and terminates any existing such declaration. It requires FDA/HHS to reinstate an in-person dispensing REMS for abortion drugs, prohibits exercising enforcement discretion to relax REMS obligations, and conditions any REMS changes on complete state submission of standardized abortion data to CDC.
Who It Affects
This bill directly affects HHS and FDA officials, manufacturers and distributors of drugs used for abortion, clinics and medical facilities that dispense those drugs, telemedicine and mail-order pharmacy providers, and state public health agencies responsible for abortion reporting.
Why It Matters
HB1525 removes federal flexibility to respond to abortion-related public health issues, restores an in-person-only distribution model for abortion drugs, and creates a nationwide data-reporting precondition that could effectively prevent future REMS updates absent full state participation. Compliance, privacy, and access consequences will reach public-health data systems, clinical workflows, and telemedicine providers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill has two linked strands: a categorical bar on federal emergency action related to abortion, and a set of hard constraints around how abortion drugs are regulated and tracked. First, it amends the Public Health Service Act framework by directing the Secretary of HHS not to use or declare a public health emergency under sections 319 or 319F–3 with respect to abortion; if any such declaration exists at enactment, the bill ends it immediately.
Practically, that removes one statutory route by which HHS could loosen rules or authorize alternate delivery of medical services tied to an emergency determination.
Second, HB1525 imposes specific constraints on the FDA’s REMS authority for abortion drugs. It bars HHS and FDA officials from using enforcement discretion regarding any REMS elements tied to abortion drugs and requires immediate reinstatement of an in-person dispensing requirement: those drugs must be given only in clinics, medical offices, or hospitals and only by or under the supervision of a ‘‘certified health care provider.’' The bill also defines that certified provider role by reference to a Prescriber Agreement Form and lists clinical capabilities required of the provider, such as accurate gestational dating, ectopic pregnancy diagnosis, and plans for surgical backup if needed.Finally, the bill conditions any future reduction of REMS protections on a data precondition: the FDA may not reduce REMS protections until every State submits aggregate abortion data to CDC’s abortion surveillance system using a standardized worksheet that includes mandatory variables (maternal age, gestational age, race and ethnicity, method, prior pregnancy history, residence, survival of the child, congenital anomalies, and more).
The bill ties those required variables to section 1903(bb) of the Social Security Act, treating them as mandatory questions for reporting purposes. In short, the bill couples product-distribution rules to a national surveillance threshold that every State must meet before REMS can be loosened.
The Five Things You Need to Know
The bill amends the Public Health Service Act by prohibiting the Secretary of HHS from using or declaring a public health emergency under sections 319 or 319F–3 with respect to abortion and immediately terminates any such declaration in effect at enactment.
It requires HHS/FDA to reinstate, effective on enactment, a REMS in-person dispensing requirement that abortion drugs be dispensed only in clinics, medical offices, or hospitals by or under the supervision of a certified health care provider.
HB1525 forbids HHS, FDA, or any HHS official from exercising enforcement discretion with respect to any requirement in the REMS applicable to abortion drugs.
The bill conditions any reduction of REMS protections on every State submitting aggregate abortion data to CDC’s abortion surveillance system entered into a standardized worksheet containing mandatory variables (including gestational age, maternal race/ethnicity, abortion method, prior pregnancies, residence, and whether the child survived).
The bill defines a ‘‘certified health care provider’’ by a Prescriber Agreement Form that requires specific clinical competencies (accurate pregnancy dating, ectopic pregnancy diagnosis, ability or arrangements for surgical intervention) and adherence to REMS use guidelines for mifepristone.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Prohibits HHS emergency declarations related to abortion; terminates existing declarations
This provision directs the Secretary of HHS not to use or declare any public health emergency under section 319 or 319F–3 of the Public Health Service Act with respect to abortion. It also ends, as of the bill’s enactment, any such declaration that is already in effect. Operationally, the clause removes a statutory pathway that HHS could use to authorize temporary regulatory changes, emergency distribution channels, or other time-limited flexibility tied to a declared public health emergency concerning abortion.
REMS enforcement and immediate reinstatement of in‑person dispensing
This subsection prevents HHS, FDA, or any HHS official from exercising enforcement discretion with respect to REMS requirements that apply to abortion drugs and requires reinstating the in-person dispensing element of the REMS effective on enactment. Practically, manufacturers, distributors, and clinicians can no longer rely on agency leniency to permit remote prescribing, pharmacy mailing, or other non‑clinic dispensing models for drugs covered by the REMS; the statutory language makes the in-person rule mandatory and enforceable by the agency.
Data precondition for changing REMS and mandatory reporting variables
Before FDA may reduce REMS protections, the bill requires that every State submit aggregate abortion data to the CDC abortion surveillance system in a standardized worksheet that includes a specific set of mandatory variables (maternal age, gestational age, race, ethnicity, method, prior pregnancy history, residence, survival of the child, congenital anomalies, etc.). The bill expressly ties those variables to section 1903(bb) of the Social Security Act, treating them as mandatory reporting questions; that creates a nationwide data threshold that must be met before REMS can be loosened.
Definitions: abortion, abortion drug, certified provider, unborn child
This subsection supplies operative definitions used elsewhere in the bill. ‘‘Abortion’’ is broadly defined to include any instrument, medicine, drug, or other substance used with the intent to end a pregnancy, with limited exceptions (viability-related procedures, ectopic treatment, removal of a dead unborn child). ‘‘Abortion drug’’ covers any medicine or combination used for an abortion. ‘‘Certified health care provider’’ is defined by the Prescriber Agreement Form and listed clinical competencies, creating a standards-based gating mechanism for who may supervise dispensing. The bill also defines ‘‘unborn child’’ as beginning at fertilization for purposes of the text.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- HHS and FDA officials favoring limits on emergency powers: the bill removes a statutory route for emergency-based regulatory changes related to abortion, simplifying the universe of permissible federal action on that topic.
- Organizations and states seeking stricter controls on distribution of abortion drugs: reinstating an in-person REMS and banning enforcement discretion creates a durable federal floor for clinic-based dispensing.
- CDC and public-health researchers focused on surveillance: the standardized variables requirement, if implemented, would produce more consistent national data for analysis of gestational age, method types, congenital anomalies, and other epidemiologic questions.
Who Bears the Cost
- Telemedicine providers and mail-order pharmacies that have developed remote prescribing or home-delivery models for abortion drugs: they would lose those delivery channels and face regulatory noncompliance or business-model disruption.
- State public health agencies and the CDC: the bill places a new data-collection and reporting burden on states, requiring standardized worksheets and aggregate submission for every mandated variable, which will consume analytic and IT resources.
- Clinics and hospitals required to implement supervised in-person dispensing: facilities must ensure certified providers are available, sign Prescriber Agreement Forms, maintain backup surgical plans, and manage patient flows that previously could have been remote.
- Patients seeking medication abortion, particularly those in rural or underserved areas: requiring in-person dispensing increases travel, time, and potentially out-of-pocket costs and may delay care, especially where clinic access is limited.
Key Issues
The Core Tension
The central tension is between imposing a uniform, clinic‑based regulatory floor and robust national surveillance on one hand, and preserving federal and clinical flexibility to adapt drug-distribution practices and protect patient access and privacy on the other—HB1525 solves for standardization and stricter controls but does so by removing discretionary tools commonly used in public-health emergencies and by creating a practically unattainable data precondition for future REMS changes.
The bill crafts a tight link between product-distribution controls (REMS) and a national surveillance threshold that every State must meet before the FDA may loosen REMS protections. That coupling raises implementation questions: what constitutes acceptable ‘‘submission’’ to CDC (file format, verification, timeliness), who funds the technical work to create the standardized worksheet and upload state data, and whether CDC must certify completeness.
The statutory tie-in to section 1903(bb) appears designed to make the listed variables mandatory for reporting, but the mechanism for enforcement and the interplay with existing state reporting laws is unspecified.
Operationally, reinstating and rigidly enforcing an in‑person REMS immediately upon enactment will affect current agency practices and product distribution chains. The prohibition on ‘‘enforcement discretion’’ removes a tool FDA and HHS often use to manage scarce capacity or respond to emergent clinical circumstances; it does not, however, create a new private-right-of-action or specify enforcement remedies, leaving open how noncompliance would be pursued.
The bill also demands sensitive individual-level variables be reported in aggregate; privacy protections, de‑identification standards, and potential conflict with state confidentiality laws are not addressed. Finally, the bill’s definitional choices (for example, defining ‘‘unborn child’’ from fertilization and broadly defining ‘‘abortion drug’’) could create downstream interpretive disputes about which products and clinical actions fall within the statute.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.